Efficacy of CMX001 as a prophylactic and presymptomatic antiviral agent in new zealand white rabbits infected with rabbitpox virus, a model for orthopoxvirus infections of humans

Viruses

Volumn 3, Issue 2, 2011, Pages 63-82

  Rice, Amanda D ^a   Adams, Mathew M ^a   Lampert, Bernhard ^b   Foster, Scott ^b   Lanier, Randall ^b   Robertson, Alice ^b   Painter, George ^b   Moyer, Richard W ^a  

^a UNIVERSITY OF FLORIDA   (United States)

^b Chimerix Inc   (United States)

Author keywords

Antiviral; CMX001; Poxvirus; Rabbitpox; Smallpox treatment

Indexed keywords

CIDOFOVIR 3 HEXADECYLOXYPROPYL ESTER;

BODY TEMPERATURE; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG ACTIVITY; DRUG EFFICACY; DRUG MEGADOSE; EAR DISEASE; EXPERIMENTAL RABBIT; FEVER; LETHALITY; LOW DRUG DOSE; MORBIDITY; MORNING DOSAGE; MORTALITY; MOUTH DISEASE; NECROSIS; NONHUMAN; NOSE DISEASE; ORTHOPOXVIRUS; POXVIRUS; POXVIRUS INFECTION; RESPIRATORY DISTRESS; REVIEW; RISK REDUCTION; SMALLPOX; SURVIVAL TIME; SYMPTOMATOLOGY; TREATMENT RESPONSE; VIROGENESIS; VIRUS REPLICATION; WEIGHT CHANGE; WEIGHT GAIN;

ANIMALS; ANTIVIRAL AGENTS; BIOTERRORISM; CYTOSINE; DISEASE MODELS, ANIMAL; DISEASE TRANSMISSION, INFECTIOUS; HUMANS; MONKEYPOX; PHOSPHONIC ACIDS; RABBITS; SMALLPOX; SMALLPOX VACCINE; VACCINIA VIRUS;

ANIMALIA; MONKEYPOX VIRUS; ORTHOPOXVIRUS; ORYCTOLAGUS CUNICULUS; POXVIRIDAE; RABBITPOX VIRUS; VARIOLA VIRUS;

EID: 79952152606     PISSN: None     EISSN: 19994915     Source Type: Journal    
DOI: 10.3390/v3020063     Document Type: Review

References (47)

1. Henderson, D.A. Bioterrorism as a public health threat. Emerg. Infect. Dis. 1998, 4, 488-492.
2. Henderson, D.A. Biopreparedness and public health. Am. J. Public Health 2001, 91, 1917-1919.
3. Bronze, M.S.; Huycke, M.M.; Machado, L.J.; Voskuhl, G.W.; Greenfield, R.A. Viral agents as biological weapons and agents of bioterrorism. Am. J. Med. Sci. 2002, 323, 316-325.
4. Food and Drug Administration, HHS. New drug and biological drug products; evidence needed to demonstrate effectiveness of new drugs when human efficacy studies are not ethical or feasible. Final rule. Fed. Regist. 2002, 67, 37988-37998.
5. Esposito, J.; Fenner, F. Poxviruses. In Fields Virology, 4th ed.; Knipe, D.E., Howley, P.M., Eds.; Lippincott Williams & Wilkins: Philadelphia, PA, USA, 2001; pp. 2885-2922.
6. Jansen, J. Eperimenteel onderzoek van Kon-. ijnensterfte door een filtreebaar virus. Tijdschr.Diergeneeskd. 1942, 69, 505-514.
7. Xing, K.; Deng, R.; Wang, J.; Feng, J.; Huang, M.; Wang, X. Genome-based phylogeny of poxvirus. Intervirology 2006, 49, 207-214.
8. Gubser, C.; Hue, S.; Kellam, P.; Smith, G.L. Poxvirus genomes: A phylogenetic analysis. J. Gen. Virol. 2004, 85, 105-117.
9. Moss, B. Poxviridae and Their Replication. In Virology, 2nd ed.; Fields, B.N., Knipe, D.E., Eds.; Raven Press: New York, NY, USA, 1990; pp. 2079-2112.
10. Moss, B. Poxviridae: The viruses and their replication. In Fields Virology, 3rd ed.; Fields, B.N., Knipe, D.M., Howley, P.M., Eds.; Lippincott-Reven: Philadelphia, PA, USA, 1996; Volume 2, pp. 2637-2672.
11. Werden, S.J.; Rahman, M.M.; McFadden, G. Poxvirus host range genes. Adv. Virus Res. 2008, 71, 135-171.
12. Li, Y.; Carroll, D.S.; Gardner, S.N.; Walsh, M.C.; Vitalis, E.A.; Damon, I.K. On the origin of smallpox: correlating variola phylogenics with historical smallpox records. Proc. Natl. Acad. Sci. U. S. A. 2007, 104, 15787-15792.
13. Chen, W.; Drillien, R.; Spehner, D.; Buller, R.M. Restricted replication of ectromelia virus in cell culture correlates with mutations in virus-encoded host range gene. Virology 1992, 187, 433-442.
14. Perkus, M.E.; Goebel, S.J.; Davis, S.W.; Johnson, G.P.; Limbach, K.; Norton, E.K.; Paoletti, E. Vaccinia virus host range genes. Virology 1990, 179, 276-286.
15. Fenner, F.; Henderson, D.A.; Arita, I.; Jezek, Z.; Ladnyi, I.D. The pathogenesis, pathology and immunology of smallpox and vaccinia. In Smallpox and Its Eradication; World Health Organization: Geneva, Switzerland, 1988; pp. 121-168.
16. Fenner, F.; Henderson, D.A.; Arita, I.; Jezek, Z.; Ladnyi, I.D. Variola virus and the other orthopoxviruses. In Smallpox and its Eradication; World Health Organization: Geneva, Switzerland, 1988; pp. 69-120.
17. Li, G.; Chen, N.; Roper, R.L.; Feng, Z.; Hunter, A.; Danila, M.; Lefkowitz, E.J.; Buller, R.M.; Upton, C. Complete coding sequences of the rabbitpox virus genome. J. Gen. Virol. 2005, 86, 2969-2977.
18. Bedson, H.S.; Duckworth, M.J. Rabbit pox: An experimental study of the pathways of infection in rabbits. J. Pathol. Bacteriol. 1963, 85, 1-20.
19. Adams, M.M.; Rice, A.D.; Moyer, R.W. Rabbitpox virus and vaccinia virus infection of rabbits as a model for human smallpox. J.Virol. 2007, 81, 11084-11095
20. Westwood, J.C.; Boulter, E.A.; Bowen, E.T.; Maber, H.B. Experimental respiratory infection with poxviruses. I. Clinical virological and epidemiological studies. Br. J. Exp. Pathol. 1966, 47, 453-465.
21. Wehrle, P.F.; Posch, J.; Richter, K.H.; Henderson, D.A. An airborne outbreak of smallpox in a German hospital and its significance with respect to other recent outbreaks in Europe. Bull. World Health Organ. 1970, 43, 669-679.
22. Nalca, A.; Hatkin, J.M.; Garza, N.L.; Nichols, D.K.; Norris, S.W.; Hruby, D.E.; Jordan, R. Evaluation of orally delivered ST-246 as postexposure prophylactic and antiviral therapeutic in an aerosolized rabbitpox rabbit model. Antivir. Res. 2008, 79, 121-127.
23. Garza, N.L.; Hatkin, J.M.; Livingston, V.; Nichols, D.K.; Chaplin, P.J.; Volkmann, A.; Fisher, D.; Nalca, A. Evaluation of the efficacy of modified vaccinia Ankara (MVA)/IMVAMUNE against aerosolized rabbitpox virus in a rabbit model. Vaccine 2009, 27, 5496-5504.
24. FDA grants marketing clearance of Vistide for the treatment of CMV retinitis. AIDS Patient Care STDS 1996, 10, 383-384.
25. Food and Drug Administration. FDA approves cidofovir for treatment of CMV retinitis. J. Int. Assoc. Physicians AIDS Care 1996, 2, 30.
26. Bray, M.; Martinez, M.; Smee, D.F.; Kefauver, D.; Thompson, E.; Huggins, J.W. Cidofovir protects mice against lethal aerosol or intranasal cowpox virus challenge. J. Infect. Dis. 2000, 181, 10-19.
27. Smee, D.F.; Sidwell, R.W.; Kefauver, D.; Bray, M.; Huggins, J.W. Characterization of wild-type and cidofovir-resistant strains of camelpox, cowpox, monkeypox, and vaccinia viruses. Antimicrob. Agents Chemother. 2002, 46, 1329-1335.
28. Baker, R.; Bray, M.; Huggins, J.W. Potential antiviral therapeutics for smallpox, monkeypox and other orthopoxvirus infections. Antivir. Res. 2003, 57, 13-23.
29. Kornbluth, R.S.; Smee, D.F.; Sidwell, R.W.; Snarsky, V.; Evans, D.H.; Hostetler, K.Y. Mutations in the E9L polymerase gene of cidofovir-resistant vaccinia virus strain WR are associated with the drug resistance phenotype. Antimicrob. Agents Chemother. 2006, 50, 4038-4043.
30. Magee, W.C.; Hostetler, K.Y.; Evans, D.H. Mechanism of inhibition of vaccinia virus DNA polymerase by cidofovir diphosphate. Antimicrob. Agents Chemother. 2005, 49, 3153-3162.
31. Araya, C.E.; Lew, J.F.; Fennell, R.S.; Neiberger, R.E.; Dharnidharka, V.R. Intermediate dose cidofovir does not cause additive nephrotoxicity in BK virus allograft nephropathy. Pediatr. Transplant. 2008, 12, 790-795.
32. Ciesla, S.L.; Trahan, J.; Wan, W.B.; Beadle, J.R.; Aldern, K.A.; Painter, G.R.; Hostetler, K.Y. Esterification of cidofovir with alkoxyalkanols increases oral bioavailability and diminishes drug accumulation in kidney. Antivir. Res. 2003, 59, 163-171.
33. Painter, G.R.; Hostetler, K.Y. Design and development of oral drugs for the prophylaxis and treatment of smallpox infection. Trends Biotechnol. 2004, 22, 423-427.
34. Foster, S. Chimerix, Inc, Durham, NC, USA. Unpublished work, 2010.
35. Hostetler, K.Y. Alkoxyalkyl prodrugs of acyclic nucleoside phosphonates enhance oral antiviral activity and reduce toxicity: current state of the art. Antivir. Res. 2009, 82, A84-A98.
36. Hostetler, K.Y.; Beadle, J.R.; Trahan, J.; Aldern, K.A.; Owens, G.; Schriewer, J.; Melman, L.; Buller, R.M. Oral 1-O-octadecyl-2-O-benzyl-sn-glycero-3-cidofovir targets the lung and is effective against a lethal respiratory challenge with ectromelia virus in mice. Antivir. Res. 2007, 73, 212-218.
37. Quenelle, D.C.; Collins, D.J.; Wan, W.B.; Beadle, J.R.; Hostetler, K.Y.; Kern, E.R. Oral treatment of cowpox and vaccinia virus infections in mice with ether lipid esters of cidofovir. Antimicrob. Agents Chemother. 2004, 48, 404-412.
38. Smee, D.F.; Wong, M.H.; Bailey, K.W.; Beadle, J.R.; Hostetler, K.Y.; Sidwell, R.W. Effects of four antiviral substances on lethal vaccinia virus (IHD strain) respiratory infections in mice. Int. J. Antimicrob. Agents 2004, 23, 430-437.
39. Rao, A.R. Smallpox; The Kothari Book Depot: Bombay, India, 1972.
40. Martin, D.B. The cause of death in smallpox: An examination of the pathology record. Mil. Med. 2002, 167, 546.
41. Jahrling, P.B.; Hensley, L.E.; Martinez, M.J.; Leduc, J.W.; Rubins, K.H.; Relman, D.A.; Huggins, J.W. Exploring the potential of variola virus infection of cynomolgus macaques as a model for human smallpox. Proc. Natl. Acad. Sci. U. S. A. 2004, 101, 15196-15200.
42. Stanford, M.M.; McFadden, G.; Karupiah, G.; Chaudhri, G. Immunopathogenesis of poxvirus infections: forecasting the impending storm. Immunol. Cell Biol. 2007, 85, 93-102.
43. Boulter, E.A.; Maber, H.B.; Bowen, E.T. Studies on the physiological disturbances occurring in experimental rabbit pox: an approach to rational therapy. Br. J. Exp. Pathol. 1961, 42, 433-444.
44. Boulter, E.A.; Westwood, J.C.; Maber, H.B. Value of serotherapy in a virus disease (rabbit pox). Lancet 1961, 2, 1012-1015.
45. Condit, R.C.; Motyczka, A. Isolation and preliminary characterization of temperature-sensitive mutants of vaccinia virus. Virology 1981, 113, 224-241.
46. Condit, R.C.; Motyczka, A.; Spizz, G. Isolation, characterization, and physical mapping of temperature-sensitive mutants of vaccinia virus. Virology 1983, 128, 429-443.
47. Jordon, R.; Leeds, J.M.; Tyavanagimatt, S.; Hruby, D.E. Development of ST-246 for Treatment of Poxvirus Infections. Viruses 2010, 2, 2409-2435.